Compositions and methods for treating inflammatory arthritis
AssigneeThe University of Hong Kong
InventorYok-Lam Kwong
Life of this patent
Estimating the term…
Abstract
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule.
Claims22
A method for degradation of IL-6 receptor expressed in fibroblast-like synoviocytes in a human subject with arthritis, the method comprising
- administering to the human subject with arthritis an oral dosage unit containing between about 1 and 10 mg arsenic trioxide, wherein the administered oral dosage unit of arsenic causes degradation of IL-6 receptor by degrading the gp130 subunit without causing degradation of the IL-6 receptor α subunit of the IL-6 receptor expressed in fibroblast-like synoviocytes in the human subject with arthritis.
A method comprising administering to a human subject with arthritis an oral dosage unit containing between about 1 and 10 mg arsenic trioxide wherein the administered oral dosage unit of arsenic causes degradation of IL-6 receptor by degrading the gp130 subunit without causing degradation of the IL-6 receptor a subunit of the IL-6 receptor expressed in fibroblast-like synoviocytes.
A method for degradation of IL-6 receptor expressed in fibroblast-like synoviocytes in a human subject with arthritis, the method comprising
- administering to the human subject with arthritis an oral dosage unit containing an amount of arsenic trioxide sufficient to cause, when administered to the human subject with arthritis, degradation of IL-6 receptor by degrading the gp130 subunit without causing degradation of the IL-6 receptor a subunit of the IL-6 receptor expressed in fibroblast-like synoviocytes in the human subject with arthritis,
- wherein the administered oral dosage unit of arsenic causes degradation of IL-6 receptor expressed in fibroblast-like synoviocytes in the human subject with arthritis.
A method for degradation of IL-6 receptor expressed in fibroblast-like synoviocytes in a human subject with arthritis, the method comprising
- administering to the human subject with arthritis an oral dosage unit of arsenic trioxide containing an amount of arsenic trioxide effective to cause degradation of the gp130 subunit in the absence of degradation of the IL-6 receptor a subunit of the IL-6 receptor expressed in fibroblast-like synoviocytes in the human subject with arthritis.
A method of inhibiting fibroblast-like synoviocyte cell proliferation in a human subject with arthritis, the method comprising
- administering to the human subject with arthritis an oral dosage unit of arsenic trioxide containing an amount of arsenic trioxide effective to inhibit fibroblast-like synoviocyte cell proliferation via a caspase-independent pathway.
Dependencies are inferred from the claim text.